Organization
Chao Family Comprehensive Cancer Center, University of California, Irvine, CA
1 abstract
Abstract
Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA,